Current research indicates that the prevalence and impact of NAFLD is continuing to increase, making NASH potentially the most common cause of advanced liver disease in coming decades.

The term NAFLD encompasses a wide range of conditions, ranging from macrovesicular steatosis, NASH which is fatty liver with inflammation, fibrosis, and cirrhosis. NASH represents the more severe end of the spectrum of non-alcoholic fatty liver disease and differs from the simple accumulation of fat in the liver, which has a more vague set of symptoms and diagnostic criteria.
However, NAFLD is associated with higher levels of glycated haemoglobin, triglyceride: high density lipoprotein cholesterol ratio, insulin resistance, and liver enzymes (alanine aminotransferase, aspartate aminotransferase, and y-glutamyltransferase). NAFLD is universally considered as the hepatic manifestation of the metabolic syndrome (MS) and insulin resistance is regarded as its key pathophysiological hallmark. Symptoms of NAFLD are vague, but it has a strong association with central obesity, reduced glucose tolerance, type 2 diabetes mellitus, arterial hypertension and hypertriglyceridaemia.

To register, please visit www.seroyal.com/education/programs-and-courses/non-alcoholic-fatty-liver-disease-nafld-epidemiology-pathophysiology-diagnosis-and-treatment.html

†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.